Table 7 Risk of variations in clinical and biochemical data stratified by CD36 gene methylation in the control, obese and obese diabetic groups

Body mass index (0/1)

1.48 [0.83–2.65]; 0.18

0.89 [0.72–1.11]; 0.31

1.36 [0.55–3.36]; 0.51

Waist size (0/1)

0.99 [0.85–1.15]; 0.88

0.99 [0.91–1.08]; 0.83

0.96 [0.79–1.78]; 0.72

Percent body fat (0/1)

0.99 [0.70–1.40]; 0.94

0.99 [0.73–1.35]; 0.95

0.42 [0.18–0.94]; 0.04*

Visceral fat level

0.25 [0.05–1.15]; 0.08

1.12 [0.64–1.96]; 0.68

4.06 [0.75–21.99]; 0.10

Glycated hemoglobin (0/1)

4.40 [0.17–113.49]; 0.37

1.13 [0.41–3.09]; 0.82

0.28 [0.07–1.20]; 0.09

HOMA-IR (0/1)

1.06 [0.45 -2.49]; 0.90

0.88 [0.63–1.23]; 0.46

0.95 [0.86–1.05]; 0.29

sCD36 (0/1)

1.00 [0.99–1.00]; 0.96

1.00 [0.99–1.00]; 0.12

1.00 [0.99–1.00]; 0.35

DNMT3a (0/1)

1.01 [0.99–1.04]; 0.24

1.00 [0.98–1.03]; 0.69

0.99 [0.96–1.02]; 0.59

Total cholesterol (0/1)

2.53 [2.58–11.11]; 0.22

3.59 [0.01–1748.98]; 0.91

2.33 [0.79–6.89]; 0.13

HDL cholesterol (0/1)

3.18 [0.03–349.79]; 0.63

0.45 [0.00–5592.54]; 0.87

3.04 [0.08–108.87]; 0.54

LDL cholesterol (0/1)

3.49 [0.55–22.01]; 0.18

0.35 [0.00–74.44]; 0.70

2.02 [0.64–6.34]; 0.23

Triglycerides (0/1)

0.09 [0.01–1.90]; 0.07

0.28 [0.00–8.29]; 0.46

1.75 [0.36–8.42]; 0.48